Recursion Pharmaceuticals (NasdaqGS:RXRX) recently announced a $500 million Follow-on Equity Offering and revealed mixed earnings results for Q4 2024, which showed declining quarterly sales and ...

Recursion Pharmaceuticals is a leader in TechBio with potential to bring in $200M in near-term milestones and $20B in future ...

Q4 2024 Earnings Call Transcript February 28, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported ...

Shares of Nvidia-backed Recursion Pharmaceuticals Inc. (RXRX) ended Friday lower, extending weekly losses past 21% after ...

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) had its target price dropped by Leerink Partners from $7.00 to ...

AbbVie, Thermo Fisher Scientific, Recursion Pharmaceuticals, Bloom Energy, and Iovance Biotherapeutics are the five Biotech ...

Full Year 2024 Results Key Financial Results Revenue: US$58.8m (up 32% ...

At Recursion's recent [Learnings] Call, Co-Founder and CEO Chris Gibson welcomed investors and analysts to share exciting updates on the company's progress in decoding biology to change the way drugs ...

TD Cowen analyst Brendan Smith maintained a Hold rating on Recursion Pharmaceuticals (RXRX – Research Report) today. The company’s shares ...

Gain insights into Recursion Pharmaceuticals' Q4 2024 earnings call. Discover clinical advancements, key partnerships, and strategic plans for 2025.

Recursion Pharmaceuticals shares were down 7% to $7.12 after the company reported a fourth-quarter loss that was wider than analysts expected.

The clinical-stage TechBio company posted a loss of $0.53 per share for Q4, wider than the $0.41 loss analysts had forecast. Revenue came in at $4.55 million, significantly below the consensus ...